SCHEMBL29617533

SCHEMBL29617533

CCCCNC(=O)c1cccc(S(N)(=O)=O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.70
CA2 P00918 7/20 0.63
KMT2A Q03164 2/20 0.57
KDM4E B2RXH2 1/20 0.57
MEN1 O00255 1/20 0.57
CA1 P00915 6/20 0.53
CA12 O43570 4/20 0.53
CA3 P07451 4/20 0.53
CA4 P22748 4/20 0.53
CA6 P23280 4/20 0.53
CA5A P35218 4/20 0.53
CA7 P43166 4/20 0.53
CA9 Q16790 4/20 0.53
CA13 Q8N1Q1 4/20 0.53
CA14 Q9ULX7 4/20 0.53
CA5B Q9Y2D0 4/20 0.53
NAAA Q02083 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 2/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3843062 0.89 SMN1; SMN2 (0.74) SMN1; SMN2CA2KMT2AMEN1CA1
SCHEMBL6359372 0.87 SMN1; SMN2 (0.72) SMN1; SMN2CA2KMT2AMEN1NAAA
SCHEMBL25738470 0.87 KMT2A (0.55) SMN1; SMN2CA2KMT2AKDM4EMEN1
SCHEMBL25738414 0.84 KMT2A (0.57) SMN1; SMN2CA2KMT2AKDM4EMEN1
SCHEMBL3127370 0.84 SMN1; SMN2 (0.67) SMN1; SMN2CA2KMT2AMEN1NAAA
SCHEMBL16117373 0.83 SMN1; SMN2 (1.00) SMN1; SMN2KMT2ANAAAL3MBTL1ALDH1A1
SCHEMBL3047715 0.81 CA2 (0.50) SMN1; SMN2CA2KMT2AKDM4EMEN1
SCHEMBL14526568 0.80 SMN1; SMN2 (0.61) SMN1; SMN2CA2KMT2AMEN1NAAA
SCHEMBL2972657 0.80 SMN1; SMN2 (0.84) SMN1; SMN2KMT2ANAAAL3MBTL1ALDH1A1
SCHEMBL6258472 0.80 SMN1; SMN2 (0.79) SMN1; SMN2KDM4ENAAAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312682-B2 Selective inhibitors of carbonic anhydrase VILNIUS UNIVERSITY (LT) 2022-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312682-B2 Selective inhibitors of carbonic anhydrase CA2, CA9, CA7 SMN1; SMN2 1397/4885CA2 1/4885KMT2A 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.